Anniversary professor, Dr. M. von Ardenne (to the 100 birthday of M. von Ardenne) by Chekhun, V.F.
Experimental Oncology ���� ��������� ����� ��ecem�er�� ���    
In oncology it is continued to �e actual the pro�lem 
of working out the effective and selective modificators 
of action of conventional cytostatic means�� that has to 
enhance their antitumor effect as well to decline their 
toxic influence upon the normal tissue and organs. 
Among the variety of modificators of traditional antitu-
mor therapy hyperthermia has a special place.  Hyper-
thermia has �een known from Hippocrates time and 
turned attention of the medical scientists in the end of 
the 1�th century and received the principal new technical 
and �iological impact in ���-th of the past century.
One of the initiators of the modern development of 
hyperthermia was the outstanding scientist-physicist 
Professor M. von Ardenne�� who has contri�ute much 
for develop this promise and effective method�� espe-
cially as a whole �ody hyperthermic influence.
Institute of Experimental Pathology�� Oncology and 
Radio�iology �IEPOR�� of National Academy of Sciences 
of Ukraine �Kiev�� has started to work in thе hyperthermia 
field since 1�7� owing to the proposition from famous 
scientific triumvirate: Prof. M. von Ardenne�� Prof. B. Pa-
ton — President of National Academy of Sciences of 
Ukraine and Prof. R. Kavetsky — founder of IEPOR. At 
present the great interest is shown in Ukraine for hyper-
thermia�� especially for the using of local heating in the 
treatment of patients with malignant tumors. Special 
care was given to the pro�lem of tumor microphysiology 
modulation with the aim to enhance the hyperthermia 
efficacy. The 1�th International Symposium on clinical 
Hyperthermia was held in Kiev on May�� 1��5.
In January ���7 M. von Ardenne will �e 1�� years 
old. He was the promoter of the developing of the 
hyperthermia pro�lems in our Institute that allow to 
extend this promising method into com�ined treat-
ment of oncological patients in Ukraine�� and pay show 
much respect to this great scientist the Editorial Board 
propose some material devoting to this date.
Ardenne�� Manfred von
��.�1.1��7����.�5.1��7
Physicist and Cancer Researcher�� Prof. �r. h. c. 
mult
1925–1926 two years study of physics�� chemistry and 
mathematics at the university of Berlin 
1928–1945 erection and managing of a private re-
search institute of electron physics in 
Berlin 
1945 mem�er of the German “Reichsfors-
chungsrat”��
1945–1955 nuclear physicist in the USSR leader of 
a research institute for the development 
of industrial technologies for isotope 
separation in Sinop near Suchumi
1955–1990 CEO of the “Manfred von Ardenne Re-
search Institute” in �resden
1956 Professor at the Technical University of 
�resden
1957–1989 mem�er of the “Research Council of the 
G�R”
1961 chairman of the “Society of Medical 
Electronics” of G�R
1963–1989 vice chairman of the “Kultur�und-Frak-
tion der Volkskammer der ��R”
1965 mem�er of the “Internationalis Astonau-
tica Academia” Pans
1991–1997 CEO of the “Von Ardenne Institut fur 
Angewandte Medizimsche Forschung 
Gm�H”
Main fields of research. Pioneer work in the field 
of radio- and television engineering�� of electron- and 
ion physics of �iomedical engineering�� first realization 
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of an electronically wide�and amplifier�� development 
of the electron �eam oscilloscope of compact design�� 
first realization of the full-electronically television�� in-
vention of the night vision equipment and X-ray image 
converter�� invention and development of the scanning 
electron microscope of high resolution�� R & � work 
at the electron microscope for Siemens�� methods 
to magnetically isotope separation�� electron �eam 
multy cham�er melting furnace�� plasma torch with 
finest plasma �eam of high density�� Oxygen Multistep 
Therapy and development of the systemic Cancer 
Multistep Therapy until the clinical application in con-
ventional incura�le patients suffered from cancer with 
metastasis ���� patents in Germany and a�road.
Publications. More than �� scientific �ooks�� �eside 
them “Funk-Ruf-Buch” �1��4���� “Verstärkermeßtechnik” 
�1������� “�ie Kathodenstrahlröhre” �1����� 1��� engi���� 
“Fernsehempfang” �1��5�� 1���� engi���� “Elektronen-
Ü�ermikroskopie” �1�4��� 1�4� jap���� “Ta�ellen zur Ange-
wandten Kernphysik” �1�5������ “Ta�ellen der Elektronen-
physik�� lonenphysik und Ü�ermikroskopie” �1�5������ 
“Ta�ellen zur Angewandten Physik” �1������ 1�7����� 
“Kre�s-Mehrschntt-Therapie” �1���7�� 1�71���� “Sauer-
stoff-Mehrschntt-Therapie” �1�7��� 1��1�� 1����� 1��7�� 
1��� engi�� “Systemische Kre�s-Mehrschntt-Therapie” 
�1��7�� and more than 7�� further pu�lications.
Awards. Lei�niz-Medal of Prussian Academy of 
Science �1�41���� State prize of USSR �1�47���� Stalin prize 
of USSR �1�5����� �r. rer. nat. h. �. �� University of Greifs-    
wald �1�5����� National prizes of G�R �1�5���1���5���� 
�r. med. h. �. �� Medical Academy of �resden �1�7�����       
�r. paed. h. �. �� �resden College of Education �1�������       
Wilhelm-Ostwald-Medal of Saxon Academy of Science 
�1��5���� �iesel-medal of German Patent-Office �1������� 
Fnednch von Schiller Prize �1������� honorary citizen 
of city of �resden �1�����.
WhoLE-boDY hYPERthERMIA IN thE-SCoPE 
of MANfRED VoN ARDENNE’S SYStEMIC 
CANCER MULtIStEP thERAPY (SCMt) 
(A short statement to the 100 birthday 
of M. von Ardenne (1907–1997))
A. von Ardenne*
B. Van Ardenne Institute of Applied Medical 
Research, Dresden, Germany
In 1��4 Otto War�urg �1����1�7��� pu�lished his 
discovery of aero�e glycolysis of cancer cells [1]. 
In vitro he could proof and in 1���� confirm that tumor 
tissue in contrast to normal tissue has in presence of 
oxygen a prominent glycolytic meta�olism. Only retina 
and �rain tissue show partly glycolysis under aero�e 
conditions whereas in all other examined normal tis-
sues no such process was o�served. War�urg consid-
ered this peculiarity of cancer tissue as a “distur�ances 
of the respiration” [�]. Aero�e glycolysis of the tumor 
tissues causes the production of lactate�� which leads to 
a reduction of the extracellulary pH-value in the tumor 
tissue. This effect was o�served in human tumors�� too. 
This phenomenon can �e used to differentiate normal 
from tumor tissue [�]. The longstanding partnership 
�etween von Ardenne and War�urg was intensified in 
the �eginning of the sixties when von Ardenne develo-
ped ideas for cancer treatment �ased on War�urgs 
experiments and findings of cancer cells growth. 
�iscussions and experimental investigations were 
intensified in such a way that War�urg convinced von 
Ardenne to quit physics and concentrate on medicine�� 
especially to focus on cancer research [4].
fig. 1. Typical temperature-time course of systemic cancer 
multistep therapy �sCMT��
As early as 1��5 Voegtiin o�served a decrease 
of the pH-value in tumor tissue upon application 
of glucose [5]. He measured the pH-value with a 
pH-electrode on sarcomas and carcinomas of rat. To 
our �est knowledge it was Naeslund�� who performed 
first measurements on human gynecological tumors 
under intravenous application of glucose in 1�5� [��].
Von Ardenne and his team in �resden investigated 
the acidification of different tumor tissues also. They 
proposed an “in vivo theory of glycolytic meta�olism 
of tumors and their hyperacidification �y hypergly-
cemia” and explored the dynamic of selective hyper 
acidification of tumors �y application of glucose [7�� �]. 
They discovered that no pH-decrease occurred dur-
ing glucose infusion over many hours in the skeletal 
musculature and in the myocardium of rat [��� �]. Even 
in the �rain of rats under such conditions ��� mM��l�� 
occurred no considera�le pH-reduction [1�]. This and 
other o�servations lead to the conclusion that tumor 
tissue can �e selectively over acidified.
Von Ardenne’s main goal — was to damage me-
tastasis of unknown localizations in the �ody. Thus he 
had to ela�orate to what extend metastasis are over 
acidified. Experimental data lead to the conclusion that 
metastases even smaller then 1.5 mm� �approx 1��� 
cancer cells�� show a clear over acidification [11].
“Classical” denaturants of proteins are acid and��or 
heat. This was the starting point for von Ardenne and his 
co-worker of many years Reitnauer to ela�orate on the 
synergy of hyperthermia and over acidification in 1���� 
in order to study cancer cell damage through thermo 
sensi�ilization due to low pH-values [1�]. They discove-
red later on that this effect can even �e outperformed �y 
extreme whole-�ody hyperthermia ��ody core tempera-
ture > 4�.5 °C��. Animal models provided experimental 
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data for selective tumor acidification. By increasing the 
temperature of the tumor to 4� to 4� °C the pH-value in 
such tissue decreased a�out �.5 pH-units [1�].
Usually meta�olism is strongly activated during 
hyperthermia also in normal cells. A lack of oxygen 
and glucose as �asic elements for the ATP-synthesis 
would �e a disadvantage for normal cells in terms 
of their sta�ility. This is one of the main reasons that 
application of oxygen was implemented into the hy-
perthermia cancer therapy also [14]. This results lead 
to the three main steps of systemic Cancer Multistep 
Therapy �sCMT���� which are:
extreme whole-�ody hyperthermia
+ induced hyperglycemia
+ relative hyperoxemia
In 1�74 in the sCMT it was suggested already a 
com�ination with cytostatics and radiotherapy [15]. 
The principle of the sCMT is represented �y those 
three steps with selective la�ilization of cancer tis-
sue while sta�ilizing the healthy tissue. It should �e 
complemented �y further selective steps�� damaging 
the cancer tissues and sta�ilizing the normal tissues.
Over a period of �5 years many methods were inves-
tigated for systemic heating treatment of patients such 
as water �athes�� extra corporal heat or high-frequency 
hyperthermia. As the most promising method was found 
water-filtered infrared-A heat radiation �wIRA�� in terms 
of tolerance to human �odies simplicity and at the same 
time potency. In wIRA a�out two thirds of the irradiation 
energy is released in the corium and in deeper skin tis-
sue. Once the heat radiation reaches the vessel �ed of 
the skin�� the �lood flow distri�utes the applied energy 
through the whole organism. This principle is similar to 
an outer �ody shell heating and allows a simple tem-
perature control of the outer �ody shell and the �ody 
core. Such a whole-�ody hyperthermia system was 
realized in the whole �ody hyperthermia device called 
IRATHERM® ����. The temperature-time course of 
sCMT �Fig. 1�� shows that it is possi�le to reach a final 
temperature of over 4� °C and to apply a high dose of 
heat within �� minutes [1��].
fig. 2. Individual evaluations related to diagnosis acc. To UICC 
criteria in different tumor entites; 5% confidence interval for 
nonP�-P� limit
In 1��� Manfred von Ardenne founded at his insti-
tute in �resden a research clinic for evaluation of sCMT 
�uring a phase-I-study it was proofed that patients in 
the stage of conventional uncontrolla�le progression 
show a good systemic tolerance of sCMT with wIRA 
hyperthermia with only “minimal side effects” [17]. Five 
years later a research group at an university demon-
strated in a phase-I��II study that this therapy “does not 
lead to any serious or sustained organ dysfunction and 
can therefore �e regarded as a safe therapy” [1�].
In �resden’s sCMT clinic were given 4�� sGMT 
one-time treatments in com�ination with adapted 
chemotherapy to patients mostly with metastasis 
in the stage of uncontrolla�le progression �etween 
1����� and 1����5. The mean �ody-core temperature 
had a value of 41.� °C ± �.� °C and the maximal �lood 
glucose level one of �7.� ± �.7 mM��l during the sixty 
minutes temperature plateau Fig. � shows the results 
of different tumor entities evaluated on the �ase of 
UICC criteria [1�].
Furthermore sponsored �y the “German Cancer 
Aid” a prospective phase-I��II study was performed 
on patients with metastatic colorectal cancer at the 
University Hospital Virchow. Herein was tested a com-
�ination of sCMT and chemotherapy protocol �folic 
acid + 5-Fluorouracil + Mitomycine-C��. The whole-
�ody hyperthermia was realized �y application of wIRA�� 
where the �ody-core temperature increased to 41.� °С 
over ��� minutes as well as a 5�% enrichment of oxygen 
through inhalation. The induced hyperglycemia had a 
value of �� mM��l. �uring this study ten patients who 
did not responded to three cycles of chemotherapy 
were treated then with three cycles of sCMT plus the 
same chemotherapy. Three patients responded with 
partial remission �PR�� and in six patients progression of 
the disease �P��� was prevented. Furthermore despite 
the negative selection of patients in the control group 
almost the same results were o�tained in the progres-
sion free survival in the control and-test group [��].
�uring a pilot study 1� patients with metastasized 
adenocarcinomas ��reast�� n = 7�� ovarian�� n = 5�� 
colorectal�� n = 7�� were treated with sCMT plus che-
motherapy. All patients were refractory to standard 
chemotherapy and lived in progression �P���. The result 
of this study showed that nine patients reached a PR 
and seven a No Chance �NC��. It was impossi�le to stop 
progression in four patients [�1].
Two patients with refractory germ cell tumors were 
treated three times with sCMT plus chemotherapy 
�Ifosphamid + Car�oplatin + Etoposid��. In �oth cases 
a PR was reached after therapy completed [��].
Besides the a�ove mentioned studies there are 
three extreme whole-�ody hyperthermia phase-II 
and two phase-III studies right now �������� on-going 
in Germany. All these studies are performed under 
induced hyperglycemia and relative hyperoxemia as 
well as com�ined with chemotherapy. They all follow 
the sCMT procedure.
Manfred von Ardenne is without dou�t one of the 
most influential protagonist of hyperthermia in oncolo-
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gy�� who fought over 4� years for the vision that cancer 
cells can selectively �e damaged in com�ination with 
hyperthermia. Many groups are working today in the 
area of hyperthermia with the focus on oncology�� what 
is a proof for the rightness of his idea post mortem�� 
Manfred von Ardenne envisioned the sCMT in com�i-
nation with chemotherapy and��or radiotherapy as an 
complementary method to conventional cancer thera-
pies. In his opinion the �est timing for this therapy was 
an early stage of cancer�� prefera�ly perioperatively. 
This will �e hopefully proven in the future.
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